Rocket Pharmaceuticals (RCKT) Research & Development (2014 - 2026)

Rocket Pharmaceuticals has reported Research & Development for 13 years, with the latest figure at $31.5 million in Q1 2026.

• Quarterly Research & Development fell 12.49% year-over-year to $31.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $137.5 million (down 15.09% YoY) and the FY2025 annual result came in at $142.0 million, down 17.07% from the prior year.
• Research & Development climbed to $31.5 million in Q1 2026 per RCKT's latest filing, from $29.3 million in the prior quarter.
• Over five years, Research & Development peaked at $51.4 million in Q2 2023 and troughed at $29.3 million in Q4 2025.
• A 5-year average of $41.0 million and a median of $42.3 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development jumped 68.59% in 2022, then fell 21.44% in 2025.
• Over 5 years, Research & Development stood at $50.0 million in 2022, then slipped by 16.57% to $41.7 million in 2023, then retreated by 10.51% to $37.4 million in 2024, then dropped by 21.44% to $29.3 million in 2025, then grew by 7.18% to $31.5 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $31.5 million, $29.3 million, and $34.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.